J Korean Med Sci.  2024 May;39(18):e150. 10.3346/jkms.2024.39.e150.

Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study

• Han HJ
• Kim SW
• Kim H
• So J
• Lee EJ
• Lim YM
• Lee JH
• Lee MA
• Kim BJ
• Baek SH
• Lee HS
• Sohn E
• Kim S
• Park JS
• Kang M
• Park HJ
• Yoon BA
• Kim JK
• Seok HY
• Kim S
• Min JH
• Chung YH
• Cho JH
• Kim JE
• Oh Si
• Shin HY

• KMID: 2555500
• DOI: http://doi.org/10.3346/jkms.2024.39.e150

Abstract

Background
During the coronavirus disease 2019 (COVID-19) pandemic, patients with myasthenia gravis (MG) were more susceptible to poor outcomes owing to respiratory muscle weakness and immunotherapy. Several studies conducted in the early stages of the COVID-19 pandemic reported higher mortality in patients with MG compared to the general population. This study aimed to investigate the clinical course and prognosis of COVID-19 in patients with MG and to compare these parameters between vaccinated and unvaccinated patients in South Korea.
Methods
This multicenter, retrospective study, which was conducted at 14 tertiary hospitals in South Korea, reviewed the medical records and identified MG patients who contracted COVID-19 between February 2022 and April 2022. The demographic and clinical characteristics associated with MG and vaccination status were collected. The clinical outcomes of COVID-19 infection and MG were investigated and compared between the vaccinated and unvaccinated patients.
Results
Ninety-two patients with MG contracted COVID-19 during the study. Nine (9.8%) patients required hospitalization, 4 (4.3%) of whom were admitted to the intensive care unit. Seventy-five of 92 patients were vaccinated before contracting COVID-19 infection, and 17 were not. During the COVID-19 infection, 6 of 17 (35.3%) unvaccinated patients were hospitalized, whereas 3 of 75 (4.0%) vaccinated patients were hospitalized (P < 0.001). The frequencies of ICU admission and mechanical ventilation were significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.019 and P = 0.032, respectively). The rate of MG deterioration was significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.041). Logistic regression after weighting revealed that the risk of hospitalization and MG deterioration after COVID-19 infection was significantly lower in the vaccinated patients than in the unvaccinated patients.
Conclusion
This study suggests that the clinical course and prognosis of patients with MG who contracted COVID-19 during the dominance of the omicron variant of COVID-19 may be milder than those at the early phase of the COVID-19 pandemic when vaccination was unavailable. Vaccination may reduce the morbidity of COVID-19 in patients with MG and effectively prevent MG deterioration induced by COVID-19 infection.

Keyword

Myasthenia Gravis; COVID-19 Infection; Vaccination; Outcomes; Worsening

Reference

1. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016; 375(26):2570–2581. PMID: 28029925.

2. Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019; 60(6):693–699. PMID: 31469909.

3. Kassardjian CD, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, et al. Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol. 2020; 27(4):702–708. PMID: 31997519.

4. Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018; 265(6):1251–1258. PMID: 29372387.

5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708–1720. PMID: 32109013.

6. Alcantara M, Koh M, Park AL, Bril V, Barnett C. Outcomes of COVID-19 infection and vaccination among individuals with myasthenia gravis. JAMA Netw Open. 2023; 6(4):e239834. PMID: 37097637.

7. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report. Updated September 29, 2023. Accessed October 16, 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports .

8. Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020; 19(12):970–971. PMID: 33212055.

9. Jakubíková M, Týblová M, Tesař A, Horáková M, Vlažná D, Ryšánková I, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021; 28(10):3418–3425. PMID: 34080271.

10. Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, et al. COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve. 2021; 64(2):206–211. PMID: 34031902.

11. Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, et al. Characteristics, treatment, and outcomes of myasthenia gravis in COVID-19 patients: a systematic review. Clin Neurol Neurosurg. 2022; 213:107140. PMID: 35091255.

12. Lee DW, Kim JM, Park AK, Kim DW, Kim JY, Lim N, et al. Genomic epidemiology of SARS- CoV-2 omicron variants in the Republic of Korea. Sci Rep. 2022; 12(1):22414. PMID: 36575217.

13. Korea Disease Control and Prevention Agency. The Republic of Korea COVID-19 vaccination. Updated 2020. Accessed October 16, 2023. https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&cg_code= .

14. Scarsi E, Massucco S, Ferraro PM, Cella A, Grisanti SG, Assini A, et al. Comparing the impact of COVID-19 on vaccinated and unvaccinated patients affected by myasthenia gravis. Life (Basel). 2023; 13(4):1064. PMID: 37109594.

15. Županić S, Perić Šitum M, Majdak M, Karakaš M, Bašić S, Sporiš D. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg. 2021; 121(4):1039–1044. PMID: 33797054.

16. Karimi N, Fatehi F, Okhovat AA, Abdi S, Sinaei F, Sikaroodi H, et al. Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: a single-center study. Clin Neurol Neurosurg. 2022; 222:107441. PMID: 36174408.

17. Solé G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhour F, et al. Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology. 2021; 96(16):e2109–e2120. PMID: 33568541.

18. Ministry of Health and Welfare. COVID-19: Changes in Infectious Disease Response Over the Past 3 Years. Sejong, Korea: Ministry of Health and Welfare;2023.

19. Ministry of Health and Welfare. COVID-19, how infectious disease response has changed over the past three years. Update 2023. Accessed October 16, 2023. https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=374685&page=1 .

20. Kwon SL, Oh J. COVID-19 vaccination program in South Korea: a long journey toward a new normal. Health Policy Technol. 2022; 11(2):100601. PMID: 35127400.

21. Thomas EV, Bou G, Barton S, Hutto S, Garcia-Santibanez R. COVID-19 infection in myasthenia gravis: clinical course and outcomes. Muscle Nerve. 2023; 68(2):171–175. PMID: 37326164.

22. Camelo-Filho AE, Silva AM, Estephan EP, Zambon AA, Mendonça RH, Souza PV, et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol. 2020; 11:1053. PMID: 33013676.

23. Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health. 2022; 10(7):e961–e969. PMID: 35597249.

24. Davies MA, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health. 2022; 27(6):564–573. PMID: 35411997.

25. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022; 399(10323):437–446. PMID: 35065011.

26. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022; 116:38–42. PMID: 34971823.

27. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of omicron (B.1.1.529) and delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023; 25:100556. PMID: 36530491.

28. Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, et al. Severity and outcomes of omicron variant of SARS-CoV-2 compared to delta variant and severity of Omicron sublineages: a systematic review and metanalysis. BMJ Glob Health. 2023; 8(7):e012328.

29. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021; 26(28):2100563. PMID: 34269175.

30. Wu N, Joyal-Desmarais K, Ribeiro PA, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023; 11(5):439–452. PMID: 36780914.

31. Kim S, Jeong SH, Shin HY, Kim SW. Factors affecting the intention of COVID-19 vaccination in Korean patients with myasthenia gravis: a survey-based study. Front Neurol. 2022; 13:847873. PMID: 35989937.

32. Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2022; 22(3):357–366. PMID: 34562375.

33. Cerqueira-Silva T, Andrews JR, Boaventura VS, Ranzani OT, de Araújo Oliveira V, Paixão ES, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis. 2022; 22(6):791–801. PMID: 35366959.

34. Seok HY, Shin HY, Kim JK, Kim BJ, Oh J, Suh BC, et al. The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol. 2017; 13(4):325–330. PMID: 29057629.

35. Park JS, Eah KY, Park JM. Epidemiological profile of myasthenia gravis in South Korea using the national health insurance database. Acta Neurol Scand. 2022; 145(5):633–640. PMID: 35141872.